IDCRC Newsletter: December 2023As 2023 comes to a close, the IDCRC would like to extend our gratitude to all of our members and partners for your efforts and dedication this year. We wish you and your loved ones a joyous holiday season and a happy new year! IDCRC Profile: Mallory Shriver, MSMallory is a lead research project coordinator for the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She has been a vital member of UMB’s VTEU, supporting COVID-19 clinical trials including her part in helping develop and qualify the Meso Scale Discovery (MSD) platform for measurement of mucosal Ab responses for Mix and Match and MOMI-Vax. Mallory will be pursuing other opportunities and leaving the University of Maryland. We thank her for her contributions to the IDCRC and wish her all the best in her future endeavors. Announcing the 2023-2024 Pilot Award Recipients Congratulations to our new Pilot Award recipients! We are thrilled to welcome the following researchers to this program. The Pilot Grants program provides one-year of funding to support research projects and career development activities that will enhance the applicant’s ability to compete successfully for an independent R- or K-series award. The projects can address a variety of topics, including vaccinology, therapeutics, laboratory studies and statistics. Visit our website to learn more about the program and awardees. Juan Calix, Jr., MD, PhD Andrew Cox, MD, PhD Jose Lemme, PhD Stephanie McLaughlin, MD, MPH Laura Matrajt, PhD Manual of Procedures SectionsView approved IDCRC Manual of Procedures (MOP) sections which describe structure, operating policies, roles, and responsibilities of entities and individuals within the unit/consortium: Seeking Clinical CollaboratorsCDC/NIH collaborative study (VIRISMAP, NCT06045923) looking for clinical collaborators The CDC and NIH are currently working on a collaborative study called “Virologic and immunologic characteristics of severe mpox among persons with advanced HIV (VIRISMAP)” (NCT06045923), to enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV. VIRISMAP is a prospective cohort study enrolling eligible in-patients who are hospitalized with mpox (though the diagnosis of mpox does not need to be new) at collaborating clinical sites and gather clinical and laboratory data during their hospitalizations. Enrollment in this study should not preclude involvement in other trials (e.g. STOMP). Direct financial compensation is not available, but other resources to support study activities will be provided by CDC/NIH. Those with interest in becoming a clinical collaborator or additional questions can email poxvirus@cdc.gov. VTEU HighlightUniversity of RochesterHighlights from the most recent grant year were presented by all VTEUs at our 2023 Annual Meeting. This month we are featuring the University of Rochester. Note, these were created by the IDCRC Leadership Operations Center and is not intended to be a comprehensive list. PublicationsNOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: "Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." View recent publications below:
NewsMore than US$ 1.8 billion in support for African vaccine manufacturing, catching up missed children and pandemic preparedness approved as Gavi Board steps up efforts to tackle backsliding and fight health emergenciesThe Board of Gavi, the Vaccine Alliance announced a series of decisions to help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to future health emergencies. The decisions were taken during a two-day meeting hosted by the Government of Ghana in Accra, Ghana, from December 6-7. Following more than 18 months of close collaboration between Gavi, the African Union, and Africa CDC, the Board approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA). AVMA is an innovative financing mechanism aimed at establishing a sustainable African vaccine manufacturing industry capable of improving the region’s resilience in the face of pandemics, outbreaks and other health emergencies as well as the health of global vaccine markets. Meet UMB’s Researcher of the Year: Kathy NeuzilKathy Neuzil is the Myron M. Levine, MD, DTPH Professor of Vaccinology at the University of Maryland School of Medicine (UMSOM) and has been director of its Center for Vaccine Development and Global Health (CVD) since 2015. An internationally renowned researcher, Neuzil is sought after by the news media as a vaccine expert and is a member of the National Academy of Medicine, an elite honor reserved for individuals who have made major contributions to advancing medical science, health care, and public health. “Dr. Neuzil is a thought leader who has made pivotal contributions toward advancing the clinical science of vaccines against respiratory viruses, rotavirus, and, more recently, typhoid fever. She is a compelling speaker and advocate who seizes on critical issues and motivates the actions needed to evaluate and implement public health interventions.” Carlos del Rio, MD, named one of Georgia's Most Influential Leaders in Healthcare Carlos del Rio, MD, Emory Vaccine Center VTEU PI, was recently named one of Georgia Trend's 500 Most Influential Leaders in Healthcare. He receives this recognition for his decades of patient care, infectious disease and global health research, medical education, and healthcare administration. How Disease Risk for RSV in Seniors May be Considered Towards Vaccine ApplicationRSV may not get as much attention for seniors as other conditions associated with older adults; however, one clinician believes the virus should. “We've done a number of studies, both here in the United States and around the world, that's really demonstrated that there's this bimodal incidence of severe disease and incidence of disease in general, that attacks the very young and the very old,” said Angela Branche, MD, associate professor of medicine, University of Rochester. TrainingMentee Profile: Shannon Walker, MD Dr. Walker’s research focuses on hemostasis and thrombosis, predictive modeling, and hematology-related vaccine complications. Additionally, she is an investigator on pediatric and adult COVID-19 vaccine studies through the Job PostingsInfectious Diseases Research Job Openings
Visit the IDSA Career Center to browse other ID/HIV Medicine job postings. Funding OpportunitiesNIH Funding Opportunities Specific to COVID-19 International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) – Due August 2, 2024; 2025 Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission – Due January 07, 2026 Notice of Special Interest (NOSI): Complement in Fundamental Immunology – Due January 08, 2026 Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine –Due January 15, 2026 IDCRC StudiesActive Studies
Fully Enrolled Studies
IDCRC Concept Quick StatsICP Status
EWG Assignment
EVCP Status
Communication ResourcesPlease submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org. |